New drug shows promise for tough kidney diseases
NCT ID NCT05732402
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This study tests a new drug called povetacicept in people with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 months, with possible extensions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site (102)
Nedlands, Western Australia, 6009, Australia
-
Investigational Site (116)
Suwon, Gyeonggi-do, 16499, South Korea
-
Investigational Site (118)
Colleyville, Texas, 76034, United States
-
Investigational Site (125)
Seoul, Gyeonggi-do, 03080, South Korea
-
Investigational Site (191)
Caguas, 00725, Puerto Rico
-
Investigational Site (501)
Phoenix, Arizona, 85302, United States
-
Investigational Site (502)
Lawrenceville, Georgia, 30046, United States
-
Investigational Site (503)
Boston, Massachusetts, 02115, United States
-
Investigational Site (504)
Goyang-si, Gyeonggi-do, 10444, South Korea
-
Investigational Site (505)
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Investigational Site (506)
Valencia, California, 91335, United States
-
Investigational Site (507)
Cheonan, Chungcheongnam-do, 31151, South Korea
-
Investigational Site (508)
Brooklyn, New York, 11203, United States
-
Investigational Site (509)
Newark, New Jersey, 07103, United States
-
Investigational Site (510)
Guri-si, Gyeonggi-do, 11923, South Korea
-
Investigational Site (511)
Albany, New York, 12209, United States
-
Investigational Site (512)
Orlando, Florida, 32806, United States
-
Investigational Site (513)
Arvada, Colorado, 80002, United States
-
Investigational Site (515)
Saint Albans, Victoria, 3021, Australia
-
Investigational Site (516)
Houston, Texas, 77054, United States
-
Investigational Site (518)
Bethlehem, Pennsylvania, 18017, United States
-
Investigational Site (519)
Concord, New South Wales, 2139, Australia
-
Investigational Site (520)
Seoul, Gyeonggi-do, 03181, South Korea
-
Investigational Site (521)
Seoul, Gyeonggi-do, 05278, South Korea
-
Investigational Site (523)
Phoenix, Arizona, 85016, United States
-
Investigational Site (524)
Tucson, Arizona, 85712, United States
-
Investigational Site (525)
Tamarac, Florida, 33321, United States
-
Investigational Site (526)
Irving, Texas, 75061, United States
-
The Johns Hopkins University School of Medicine
Baltimore, Maryland, 21224, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.